Bard (C.R.) Inc. MTA
The Story of An American Company

About this book:

*Bard (C.R.) Inc.: The Story of An American Company* chronicles the remarkable journey of a medical device giant, from its humble beginnings in 1907 as a small importer of French silks and catheters to its eventual acquisition by Becton, Dickinson and Company (BD) in 2017 for $24 billion. This comprehensive history delves into the entrepreneurial vision of founder Charles Russell Bard and the strategic leadership that transformed the company into a global powerhouse in medical technology. Readers will explore Bard's pivotal role in introducing revolutionary products like the Foley catheter, its pioneering shift to synthetic materials and pre-sterilized packaging, and its ambitious expansion beyond urology into critical areas such as vascular, oncology, and surgical specialties.

The book meticulously details Bard's evolution through key phases: its early growth and the Bard-Parker partnership, the shift in ownership to Willits and Outwin, its public listing on the NYSE, and significant international expansion into markets like Canada, the UK, and Japan. It highlights the company's aggressive strategy of strategic acquisitions, integrating innovative technologies and companies like Davol and USCI, which bolstered its product portfolio in areas like angioplasty catheters, stents, and hernia mesh. However, the narrative doesn't shy away from the profound challenges Bard faced, including the devastating 1990s catheter scandal that led to criminal charges and massive fines, and the widespread legal battles over transvaginal mesh and Inferior Vena Cava (IVC) filters, which resulted in thousands of lawsuits and significant settlements.

Ultimately, *Bard (C.R.) Inc.* is more than just a corporate history; it's a compelling case study of innovation, adaptation, and the complex interplay between medical advancement, regulatory oversight, and corporate responsibility. It offers invaluable lessons on the risks and rewards of the medical device industry, illustrating how a company navigates periods of intense growth, ethical dilemmas, and market consolidation. This book is an essential read for anyone interested in the history of medicine, corporate strategy, and the intricate landscape of healthcare delivery in America and beyond, providing a balanced and insightful look at a company that profoundly shaped modern patient care.

What You'll Find Inside:

• **Century of Medical Innovation:** Explore C.R. Bard's transformation from a small importer in 1907 to a global medical technology leader, pioneering devices in urology, vascular care, oncology, and surgical specialties.
• **Pioneering Product Development:** Discover the impact of breakthrough products like the Foley catheter, angioplasty catheters, and innovative surgical mesh, and how they revolutionized patient care.
• **Strategic Growth and Global Expansion:** Understand Bard's evolution through strategic acquisitions (e.g., Davol, USCI), public offering, and significant international expansion across continents, establishing a worldwide footprint.
• **Challenges in Patient Safety and Regulation:** Gain insights into major legal and ethical controversies, including the 1990s catheter scandal and widespread litigation concerning transvaginal mesh and IVC filters, highlighting critical lessons in corporate responsibility and regulatory compliance.
• **Acquisition and Future Integration:** Learn about the 2017 acquisition by Becton, Dickinson and Company (BD) and how Bard's legacy, products, and expertise are being integrated into BD's global strategy for future innovation and market leadership.

Who's It For:

This book is ideal for individuals interested in the history of American industry, particularly the evolution of medical technology and the medical device sector. Healthcare professionals, business students, and those studying corporate strategy, regulatory affairs, or medical ethics will find valuable case studies on innovation, growth, market challenges, and the complexities of patient safety and product liability within a highly regulated industry.